{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.79","estimateComment":"HR and CI calculated using Cox Proportional Hazards model, where a HR \\< 1 favours olaparib+abiraterone. Stratification factors are the same as those used in the stratified log-rank test.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3099","paramType":"Hazard Ratio (HR)","paramValue":"1.21","statisticalComment":"Log rank test stratified by Metastases and Docetaxel at metastatic hormone-sensitive prostate cancer stage using a pre-specified pooling strategy.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"353"}],"units":"Participants"}],"description":"An event for opiate use is defined as the first opiate use for cancer related pain.","groups":[{"description":"Patients receive oral treatment with olaparib 300mg twice daily in combination with abiraterone 1000mg once daily","id":"OG000","title":"Olaparib 300 mg bd + Abiraterone 1000 mg qd"},{"description":"Patients receive oral treatment with placebo twice daily in combination with abiraterone 1000mg once daily.","id":"OG001","title":"Placebo bd + Abiraterone 1000 mg qd"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomised patients who are not on opiates at baseline","reportingStatus":"POSTED","timeFrame":"Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)","title":"Number of Participants With Opiate Use","type":"SECONDARY","unitOfMeasure":"Participants"}